Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca confirms settlement over patent infringement

AstraZeneca confirms settlement over patent infringement

26th March 2013

AstraZeneca has announced it has entered into a settlement agreement in its US patent infringement litigation regarding a proposed rosuvastatin zinc product.

The global pharmaceuticals company confirmed the outcome of the legal proceedings resulted in Watson Laboratories agreeing not to further appeal a decision by the US Courts that upheld the validity and enforceability of the Crestor substance patent.

As part of the deal, Watson and Egis Pharmaceuticals accepted that the Crestor substance patent is valid and enforceable, while it would be infringed by the former organisation's rosuvastatin zinc product and its rosuvastatin calcium offering.

The agreement comes after AstraZeneca brought suit against Watson with the allegations the firm's product infringed a substance patent covering Crestor.

Under the conclusion of the legal proceedings, AstraZeneca will now file the settlement agreement with the US Federal Trade Commission and US Department of Justice in compliance with the Medicare Prescription Drug, Improvement and Modernisation Act of 2003.ADNFCR-8000103-ID-801562260-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.